Clinical Trials in Progress

Clinical Trials in Progress

Don't miss this unique opportunity to introduce your clinical trials to the global urologic community!

About the Program

Clinical Trials in Progress is an innovative new program designed to increase awareness of important clinical trials that are expected to influence practice when they are ultimately reported and/or published.

Trials that are accepted will be featured in the new Learning Lab, which showcases engaging presentations at AUA2025. This venue will be adjacent to the Science & Technology Hall and is sure to attract a robust attendance.

Eligible Studies

Investigators can present ongoing industry-sponsored or investigator-initiated independent studies that are about to open, currently accruing participants, or in follow-up. Submissions should describe the trial's purpose, design and eligibility criteria, but have not reported primary findings.

Requirements

• The trial must be registered, open, and enrolling patients.
• The submission must not contain preliminary data or results.
• The use of proprietary drug names or the names of drug manufacturers is not permitted. If necessary, the proprietary drug name may be included in parentheses directly after the generic name on first use.
• Information about pricing, fees, or reimbursement related to trial participation is not allowed.

Submission Guidelines

Clinical Trials in Progress should be organized into two sections:

Background

• Scientific rationale for the trial
• Brief description of interventions
• Correlative studies of particular interest

Methods

• Trial design and statistical methods, highlighting any new features
• Treatment or interventions planned
• Major eligibility criteria, highlighting any unusual aspects
• Current enrollment status, without providing results or endpoints
• Phase II and III studies must state how many patients have been enrolled out of the planned total
• Phase III trials may state when the data monitoring committee last reviewed the trial and what it recommended

Review Criteria

• Strength of Science – Does the trial address an important and new question?
• Trial Design – Are the eligibility criteria, study endpoints, and planned analysis well-defined?
• Collaboration – Is there potential for investigator collaboration?
• Relevance – Will the results be relevant and of interest to the AUA Annual Meeting community?

Trials Accepted for Presentation

Accepted Clinical Trials in Progress will be scheduled in the Learning Lab according to topic category. The principal investigator (presenter) will have approximately 10 minutes to present and take questions from the audience.

Trials accepted for the Annual Meeting are copyrighted by the American Urological Association and published in a supplement of The Journal of Urology® on the first day of the Annual Meeting. No part of materials published in The Journal of Urology® may be reproduced without written permission of the publisher.

For information on requesting permission to reuse The Journal of Urology®, visit shop.lww.com/journal-permission or email publications@AUAnet.org.

Questions may be sent to speakers@AUAnet.org.